The results of the GLP-1 of the real world are not clinical trials in relation to surgery

Weight loss surgery has proven five times more effective than weekly injections of popular GLP-1 receptors, including semaglutide (such as ozempic) and shooting (like mounjaro).

The conclusion comes from a recent study presented this week at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Scientific annual in Washington.

Researchers examined data from “real” electronic medical records of 51,085 patients in Nyu Langone Health and NYC Health +hospitals.

Hairstyles and medical experts confirm temporary hair loss affecting ozempic users

All patients had a body mass index (BMI) of at least 35.

They had undergone bariatric surgery (gastrectomy of the sleeves or a red gastric puncture in-y) or were prescribed of injectable semaglutide or shooting between 2018 and 2024.

Weight loss surgery has proven five times more effective than weekly injections of popular GLP-1 receptors. (istock)

(The sleeve gastrectomy reduces stomach size to help obese patients lose weight; gastric bypass implies reachuming the digestive tract to bypass part of the small intestine, according to the Mayo clinic.)

Patients who underwent one of the bariatric surgeries had lost an average of 58 pounds two years later, while those who had taken a prescription drug GLP-1 for at least six months lost 12 pounds, according to the researchers.

Low calories diets linked to a surprising mental health effect, show new research

Surgical results marked 24% total weight loss compared to 4.7% for injectable drugs, according to the press release from the study.

Those who took the drug GLP-1 for a full year showed more weight loss (7%), but it was always less than those who had undergone one of surgeries.

Patients who underwent one of the bariatric surgeries had lost an average of 58 pounds two years later, while those who had taken a prescription drug GLP-1 for at least six months lost 12 pounds. (istock)

These results differ from the results of clinical trials.

“Clinical trials show weight loss between 15% and 21% for GLP-1, but this study suggests that the real-world weight loss is considerably lower even for patients who have active prescriptions for an entire year,” said the main study, Avery Brown, MD, a surgical resident at Nyu Langone Health, in the press release.

Click here to obtain the Fox News app

According to Brown, up to 70% of patients with GLP-1 prescriptions can interrupt treatment in a year, according to Brown.

“GLP-1 patients may need to adjust their expectations, more closely respect treatment or opt for metabolic and bariatric surgery to obtain the desired results,” he advised.

In future studies, researchers plan to explore strategies for improving results for patients taking GLP-1 and identifying patients from better candidates for surgery in relation to injectable drugs, according to the press release.

The doctor defends GLP-1

Dr. Brett Osborn, an expert in neurosurgeon and Florida longevity, stressed that bariatric surgery may include a “significant risk” and that it does not break the need for behavioral changes.

“Surgery does not teach discipline,” he told Fox News Digital. “This does not reclaim your brain. It simply narrows your stomach and hopes that you comply with a postoperative diet that most people do not have the will to follow. This is why the recurrence rate (weight reproach) is high.”

The GLP-1 agonists, on the other hand, target the command centers of the brain of appetite and satiety, noted Osborn.

“(GLP-1) decrease hunger, increase satiety and ultimately change the behavior of the interior.”

“They decrease hunger, increase satiety and ultimately change the behavior of the interior,” he said. “They don’t just change your body – they change your biology.”

The doctor also noted that GLP-1s have been linked to health benefits beyond weight loss, including a reduced risk of dementia and protection against heart disease.

“Yes, these drugs are expensive. Yes, they can cause gastrointestinal side effects. But these are manageable with monitoring of competent doctors and good education,” added Osborn.

Only approximately 1% of patients who meet the criteria of metabolic and bariatric surgeries underwent one of these procedures in 2023. (AP photo / kirsty wigglesworth, file)

The prevalence of GLP-1 drugs is higher than bariatric surgeries. Studies show that around 12% of Americans have taken a GLP-1, while 6% are currently taking them.

However, more than half of the patients stop taking them after a year and 72% abandon them after two years, revealed that research has revealed.

Click here to register for our Health Newsletter

According to ASMBS, around 1% of patients who meet the criteria of metabolic and bariatric surgeries underwent one of these procedures in 2023.

The study received funding for subsidies from the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH).

For more health items, visit www.foxnews.com/health

Novo Nordisk, manufacturer of Ozempic and Wegovy, refused a request for comments.

A spokesperson for Eli Lilly, manufacturer of Mounjaro and Zepbound, provided the statement below to Fox News Digital.

“Obesity drugs, like Zepbound, represent a significant progress in the treatment of obesity, offering a non -invasive treatment option for people living with this chronic disease. Although bariatric surgery remains an important and effective intervention for certain patients, it is not appropriate or accessible for everyone. Since obesity cannot be treated with a number of patients.”